Breaks Categories: Stock Spotlights

ThursdayApr 20, 2017 12:14 pm

NetworkNewsBreaks – MicroVision, Inc. (NASDAQ: MVIS) Secures $24M Contract for Laser Beam Scanning System by Leading Tech Company

MicroVision (NASDAQ: MVIS) shares are up 16% this morning after the company announced its contract with a major technology company to develop a Laser Beam Scanning (LBS) display system and to produce MicroVision specific components. Per the agreement, the company will develop a new generation of MEMS, ASICs and related firmware for a high resolution, LBS-based product the technology company is planning to produce. MicroVision will receive up to $24 million, including $14 million in fees for development work that is expected to span 21 months and an upfront payment for other items. The development fees would be paid upon…

Continue Reading

ThursdayApr 20, 2017 12:11 pm

NetworkNewsBreaks – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) Inks LOI with Pint Pharma; Shares Climb

Immune Pharmaceuticals (NASDAQ: IMNP) shares are up more than 48% in late morning trade following news the company has entered into a letter of intent with Pint Pharma GmnH regarding the pursuit of an exclusive license by Pint of the rights to commercialize Ceplene throughout Latin America. The companies anticipate the close of the final agreement will occur within 30 days. Per the final agreement, Pint will carry out the full commercialization of the licensed product in the territory, including Ceplene registration, pricing and reimbursement, and sales and marketing activities. At the time of the final agreement, Pint will also…

Continue Reading

ThursdayApr 20, 2017 12:07 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Launches Updated Apps with Integrated UnionPay Payment Modules

Online-to-offline (O2O) integrated social media platform operator Moxian, Inc. (NASDAQ: MOXC) this morning announced the launch of new versions of its Moxian User App and Business App that feature built-in UnionPay payment modules. This update follows Moxian’s previously announced strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay. “The implementation of UnionPay into our App is a big game changer in our strategy,” James Tan, chairman and CEO of Moxian, noted in this morning’s news release. “Through various methods, we are able to capture both users and merchants by enticing users to spend at merchant stores, which in-turn boost…

Continue Reading

WednesdayApr 19, 2017 11:15 am

NetworkNewsBreaks – Marathon Patent Group, Inc. (NASDAQ: MARA) Prices $2.66M Synchronized Registered Direct Offering and Private Placement

Marathon Patent Group (NASDAQ: MARA) recently entered into definitive agreements with investors for the purchase and sale of 3,800,000 shares of common stock at a price of $0.70 per share in a registered direct offering, as well as warrants to purchase up to 2,280,000 shares of common stock at an effective price of $0.01 per warrant with an exercise price of $0.83 per share in a concurrent private placement. Gross proceeds of the offerings are expected to be approximately $2,660,000 before fees, expenses and placement agent discounts. The company plans to use the net proceeds for working capital and other…

Continue Reading

ThursdayApr 13, 2017 12:59 pm

NetworkNewsBreaks – Relmada Therapeutics, Inc.’s (RLMD) d-Methadone Receives Fast Track Designation by FDA; Shares Rise

Relmada Therapeutics’ (OTCQB: RLMD) shares are up 20% mid-day after the company said that it has received Fast Track designation for d-Methadone from the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder. This designation offers many advantages, including more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of…

Continue Reading

ThursdayApr 13, 2017 11:51 am

NetworkNewsBreaks – SeeThruEquity Issues Updated Coverage on GEE Group, Inc. (NYSE: JOB)

SeeThruEquity has issued an update on shares of GEE Group’s (NYSE: JOB) stock following recent first quarter 2017 financial results, in which the company reported revenues of $22 million, compared to $17.6 million in the first quarter of 2016. GEE Group also recently acquired SNI Companies, a private staffing company with over $100 million in annual revenue. The analyst cited this acquisition as fuel to accelerate the company’s penetration into professional staffing and generate cash flow. For more information visit www.geegroup.com About GEE Group Inc. GEE Group Inc. is a provider of specialized staffing solutions and is the successor to…

Continue Reading

WednesdayApr 12, 2017 12:06 pm

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Schedules End of Phase 2 FDA Meeting, Initiates Phase 3 Development

Ritter Pharmaceuticals (NASDAQ: RTTR) shares are up 15% after the company said that the U.S. Food and Drug Administration (FDA) has agreed to an end of phase 2 meeting. The meeting is expected to take place in the third quarter of 2017 to discuss the results of Ritter’s recently completed phase 2b/3 trial, which demonstrated numerous positive topline results. A full analysis of the data is currently underway. The company also plans to discuss phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. "Based on the topline results of…

Continue Reading

TuesdayApr 11, 2017 11:47 am

NetworkNewsBreaks – Tonix Pharmaceuticals (NASDAQ: TNXP) Shares Rally on Results from U.S. FDA Meeting on TNX-102 SL for PTSD

Shares of Tonix Pharmaceuticals (NASDAQ: TNXP) are up 12% this morning on news that the company has received official minutes from its Initial Cross-Disciplinary Breakthrough Meeting held with the U.S. Food and Drug Administration (FDA) on March 9, 2017.  After being awarded Breakthrough Therapy designation in December 2016, Tonix was invited to meet with the FDA to evaluate the feasibility of accelerating the development and registration of TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD). “The FDA’s standard of evidence for drug approval typically requires two positive Phase 3 trials; however, following our Initial Cross-Disciplinary Breakthrough Meeting in…

Continue Reading

MondayApr 10, 2017 12:53 pm

NetworkNewsBreaks – Cemtrex, Inc. (NASDAQ: CETX) Shares Climb on Multi-Million Dollar Purchase Order, Expectations for Organic Growth

Cemtrex (NASDAQ: CETX) this morning said it has received a multi-million dollar order from HBH GmbH of Germany to build electronic components for high-power HF amplifiers for the FRIB particle accelerator at Michigan State University. The company expects to complete the order for the new customer over the next 18-month period. “We are excited to be working with HBH GmbH in supporting Michigan State University on this unique application. We believe that working on extremely complex high-tech electronics such as this validates our underlying strategy to focus on niche high-value markets. This strategy is expected to allow us to maintain…

Continue Reading

MondayApr 10, 2017 12:50 pm

NetworkNewsBreaks – Geron Corp. (NASDAQ: GERN) Shares Higher on Second Internal Data Reviews for Imetelstat Trials

Geron Corporation (NASDAQ: GERN) shares climbed 21% on news that the second internal data reviews of the company’s IMerge and IMbark clinical trials have been completed by Janssen Research & Development, LLC. IMerge, the study of the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS), demonstrated that the benefit/risk profile of imetelstat in the treated patients supports continued development. The company intends to provide the FDA with a data package and proposed trial design refinements. For IMbark, a study of imetelstat in relapsed or refractory myelofibrosis (MF), current data suggest clinical benefit and a potential overall survival benefit. The…

Continue Reading